Please try another search
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Vicki Rosen | - | - | Member of Scientific Advisory Board |
Mary L. Bouxsein | - | - | Member of Scientific Advisory Board |
Paul B. Yu | - | - | Member of Scientific Advisory Board |
Julius Knowles | 59 | 2016 | Independent Director |
Mary Ann Gray | 70 | 2020 | Independent Director |
Tomer Kariv | 62 | 2020 | Independent Director |
Ran Nussbaum | 50 | 2016 | Independent Director |
Carl L. Gordon | 58 | 2020 | Independent Chairman |
Nima Farzan | 47 | 2020 | Independent Director |
Jasbir S. Seehra | 68 | 2015 | President, CEO & Director |
Alpna H. Seth | 61 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review